Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 11, 2013, Pages 1615-1624

  Costa, Luciano J ^a   Zhang, Mei Jie ^b   Zhong, Xiaobo ^b   Dispenzieri, Angela ^c   Lonial, Sagar ^d   Krishnan, Amrita ^e   Freytes, Cesar ^f   Vesole, David ^g   Gale, Robert Peter ^h   Anderson, Kenneth ⁱ   Wirk, Baldeep ^j   Savani, Bipin N ^k   Waller, Edmund K ^d   Schouten, Harry ^l   Lazarus, Hillard ^m   Meehan, Kenneth ⁿ   Sharma, Manish ^o   Kamble, Rammurti ^p   Vij, Ravi ^q   Kumar, Shaji ^c   Nishihori, Taiga ^r   Kindwall Keller, Tamila ^s   Saber, Wael ^b   Hari, Parameswaran N ^b   more..

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c MAYO CLINIC   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j UNIVERSITY OF FLORIDA   (United States)

^k VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁿ DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^o FOX CHASE CANCER CENTER   (United States)

^p CENTER FOR CELL AND GENE THERAPY   (United States)

^q BARNES JEWISH HOSPITAL   (United States)

^r H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^s UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

Autologous stem cell transplantation; Multiple myeloma; Population study; Survival

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; BUSULFAN; CARMUSTINE; CISPLATIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 2; LENALIDOMIDE; MELPHALAN; PACLITAXEL; PLERIXAFOR; PREDNISONE; RITUXIMAB; THALIDOMIDE; THIOTEPA; VINCRISTINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; UNITED STATES; WHOLE BODY RADIATION;

AUTOLOGOUS STEM CELL TRANSPLANTATION; MULTIPLE MYELOMA; POPULATION STUDY; SURVIVAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84885803622     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.08.002     Document Type: Article

References (35)

1. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
2. Kristinsson S.Y., Landgren O., Dickman P.W., et al. Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003. JClin Oncol 2007, 25:1993-1999.
3. Brenner H., Gondos A., Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009, 94:270-275.
4. Schaapveld M., Visser O., Siesling S., et al. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 2010, 46:160-169.
5. Pulte D., Gondos A., Brenner H. Improvement in survival of older adults with multiple myeloma: Results of an updated period analysis of SEER data. Oncologist 2011, 16:1600-1603.
6. Turesson I., Velez R., Kristinsson S.Y., et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: A population-based study. JClin Oncol 2011, 28:830-834.
7. Bashir Q., Shah N., Parmar S., et al. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma 2012, 53:118-122.
8. Kumar S.K., Dingli D., Lacy M.Q., et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched-pair analysis. Am J Hematol 2008, 83:614-617.
9. Cavo M., Pantani L., Petrucci M.T., et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012, 120:9-19.
10. Rosinol L., Oriol A., Teruel A.I., et al. Superiority of bortezomib, thalidomide and dexamethasone (VTD) as induction pre-transplantation therapy in multiple myeloma: A randomized phase III PETHEMA/GEM study. Blood 2012, 120:1589-1596.
11. Harousseau J.L., Attal M., Avet-Loiseau H., et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. JClin Oncol 2010, 28:4621-4629.
12. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
13. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 2010, 376:2075-2085.
14. Durie B.G., Salmon S.E. Aclinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975, 36:842-854.
15. Greipp P.R., San Miguel J., Durie B.G., et al. International staging system for multiple myeloma. JClin Oncol 2005, 23:3412-3420.
16. Hari P.N., Zhang M.J., Roy V., et al. Is the International Staging System superior to the Durie-Salmon Staging System? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia 2009, 23:1528-1534.
17. Blade J., Samson D., Reece D., et al. Myeloma Subcommittee of the European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998, 102:1115-1123.
18. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
19. Nietfeld J.J., Pasquini M.C., Logan B.R., et al. Lifetime probabilities of hematopoietic stem cell transplantation in the US. Biol Blood Marrow Transplant 2008, 14:316-322.
20. Surveillance Epidemiology and End Results. SEER data, 1992-2011 2012, National Cancer Institute, Bethesda, MD.
21. United States Census Bureau. Suitland, MD;2012.
22. Fermand J.P., Ravaud P., Chevret S., et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998, 92:3131-3136.
23. Attal M., Harousseau J.L., Stoppa A.M., et al. Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. NEngl J Med 1996, 335:91-97.
24. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. NEngl J Med 2003, 348:1875-1883.
25. Badros A., Barlogie B., Siegel E., et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001, 114:600-607.
26. Waxman A.J., Mink P.J., Devesa S.S., et al. Racial disparities in incidence and outcome in multiple myeloma: A population-based study. Blood 2010, 116:5501-5506.
27. Verma P.S., Howard R.S., Weiss B.M. The impact of race on outcomes of autologous transplantation in patients with multiple myeloma. Am J Hematol 2008, 83:355-358.
28. Hari P.N., Majhail N.S., Zhang M.J., et al. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2010, 16:395-402.
29. Joshua T.V., Rizzo J.D., Zhang M.J., et al. Access to hematopoietic stem cell transplantation: Effect of race and sex. Cancer 2010, 116:3469-3476.
30. Kumar S.K., Dingli D., Dispenzieri A., et al. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Bone Marrow Transplant 2008, 41:1013-1019.
31. Sonneveld P., Schmidt-Wolf I.G., van der Holt B., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/GMMG-HD4 trial. JClin Oncol 2012, 30:2946-2955.
32. McCarthy P.L., Hahn T., Hassebroek A., et al. Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: Significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. Biol Blood Marrow Transplant 2013, 19:1116-1123.
33. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. NEngl J Med 2003, 349:2495-2502.
34. Cavo M., Tosi P., Zamagni E., et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. JClin Oncol 2007, 25:2434-2441.
35. Barlogie B., Jagannath S., Desikan K.R., et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93:55-65.